“The third quarter of 2023 was marked by significant progress, culminating in the presentation of favorable clinical data supporting our belief that our lead investigational candidate SNS-101 is a potentially transformative treatment in the oncology space with a best-in-class safety and pharmacokinetic profile,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. “Clinical data to-date support our capability to execute on the promise and development of conditionally active antibodies, and we believe we are well-capitalized to advance SNS-101 clinically toward our near-term business and scientific milestones.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNSE:
- Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
- Sensei Biotherapeutics reports ‘favorable’ clinical data for SNS-101
- Sensei Biotherapeutics appoints Krebs as Chief Business Officer
- Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
